Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX – Get Rating) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03), MarketWatch Earnings reports.
Brooklyn ImmunoTherapeutics stock traded down $0.06 during mid-day trading on Friday, reaching $1.64. 293,627 shares of the stock traded hands, compared to its average volume of 401,772. Brooklyn ImmunoTherapeutics has a 12-month low of $1.60 and a 12-month high of $80.67.
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Brooklyn ImmunoTherapeutics by 20.3% during the fourth quarter. BlackRock Inc. now owns 2,147,749 shares of the biotechnology company’s stock valued at $8,956,000 after purchasing an additional 361,682 shares during the period. Wells Fargo & Company MN grew its holdings in Brooklyn ImmunoTherapeutics by 103.2% during the fourth quarter. Wells Fargo & Company MN now owns 57,104 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 28,997 shares during the period. Marshall Wace LLP bought a new position in shares of Brooklyn ImmunoTherapeutics in the fourth quarter worth about $138,000. Cubist Systematic Strategies LLC bought a new position in shares of Brooklyn ImmunoTherapeutics in the fourth quarter worth about $194,000. Finally, State Street Corp boosted its stake in shares of Brooklyn ImmunoTherapeutics by 1.9% in the fourth quarter. State Street Corp now owns 509,258 shares of the biotechnology company’s stock worth $2,124,000 after acquiring an additional 9,398 shares during the period.
Brooklyn ImmunoTherapeutics Company Profile (Get Rating)
Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
- Get a free copy of the StockNews.com research report on Brooklyn ImmunoTherapeutics (BTX)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.